Celanese Corporation (CE - Free Report) will feature VitalDose ethylene vinyl acetate (EVA), a versatile polymer used in delivering controlled release medications with varying routes of administration including subcutaneous drug delivery implants at the 2016 Controlled Release Society (CRS) Annual Meeting and Exposition, from Jul 17–20 in Seattle, WA.
Celanese VitalDose EVA, a controlled release material, is meeting the increasing needs of the industry as pharmaceutical companies are searching for better administrative methods to boost efficacy and improve patient drug compliance. It helps manufacturers derive a polymer as per their needs, which would provide them the flexibility to develop controlled release devices that can be used for external or subcutaneous applications.
VitalDose EVA allows manufacturers to customize the release rate of drugs used in implantable drug delivery devices. This copolymer, which blends soundly with other polymers, can be used alone as well as with other excipients or additives to attain the required release rate. VitalDose EVA is used by pharmaceutical companies in a large range of drug delivery applications such as transdermal, subcutaneous, ocular, intravaginal, intraoral and rectal.
Celanese’s shares rose 2.8% to close at $67.14 on Jul 8.
Celanese’s adjusted earnings for first-quarter 2016 were $1.83 per share, indicating a 6% increase from the prior-year quarter. Earnings per share also beat the Zacks Consensus Estimate of $1.52. Although revenues dropped roughly 3% year over year to $1,404 million in the quarter, the figure beat the Zacks Consensus Estimate.
Celanese also upgraded its outlook for 2016. It now expects an improvement of 8%−10% in earnings per share, compared to 5%−10% growth stated earlier. The company intends to pursue commercial discipline coupled with excellence in operation and productivity, to survive and grow in the current environment.
Celanese currently carries a Zacks Rank #3 (Hold).
Better-ranked companies in the chemicals industry include Axiall Corporation , Albemarle Corporation (ALB - Free Report) and Asahi Kasei Corp. (AHKSY - Free Report) , all sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Celanese Corporation (CE - Free Report) will feature VitalDose ethylene vinyl acetate (EVA), a versatile polymer used in delivering controlled release medications with varying routes of administration including subcutaneous drug delivery implants at the 2016 Controlled Release Society (CRS) Annual Meeting and Exposition, from Jul 17–20 in Seattle, WA.
Celanese VitalDose EVA, a controlled release material, is meeting the increasing needs of the industry as pharmaceutical companies are searching for better administrative methods to boost efficacy and improve patient drug compliance. It helps manufacturers derive a polymer as per their needs, which would provide them the flexibility to develop controlled release devices that can be used for external or subcutaneous applications.
VitalDose EVA allows manufacturers to customize the release rate of drugs used in implantable drug delivery devices. This copolymer, which blends soundly with other polymers, can be used alone as well as with other excipients or additives to attain the required release rate. VitalDose EVA is used by pharmaceutical companies in a large range of drug delivery applications such as transdermal, subcutaneous, ocular, intravaginal, intraoral and rectal.
Celanese’s shares rose 2.8% to close at $67.14 on Jul 8.
Celanese’s adjusted earnings for first-quarter 2016 were $1.83 per share, indicating a 6% increase from the prior-year quarter. Earnings per share also beat the Zacks Consensus Estimate of $1.52. Although revenues dropped roughly 3% year over year to $1,404 million in the quarter, the figure beat the Zacks Consensus Estimate.
Celanese also upgraded its outlook for 2016. It now expects an improvement of 8%−10% in earnings per share, compared to 5%−10% growth stated earlier. The company intends to pursue commercial discipline coupled with excellence in operation and productivity, to survive and grow in the current environment.
Celanese currently carries a Zacks Rank #3 (Hold).
Better-ranked companies in the chemicals industry include Axiall Corporation , Albemarle Corporation (ALB - Free Report) and Asahi Kasei Corp. (AHKSY - Free Report) , all sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on ALB - FREE
Get the latest research report on CE - FREE
Get the latest research report on AHKSY - FREE